AbbVie and Xilio Therapeutics have inked a collaboration and option-to-license agreement potentially worth more than $2 billion to clinical-stage biotechnology company Xilio.

CNTXT and Oracle continue to advance their strategic collaboration, reinforcing their shared vision for AI innovation and ...

Riyadh, KSA - Elm, a leading digital solutions provider, has signed a Memorandum of Understanding (MoU) with Lean Business ...

DeepTempo announced today that it has completed the BNY Ascent Program. As part of the program, DeepTempo worked with BNY on ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor ...

As we approach 2025, innovation is evolving at an unprecedented pace. Visionary leaders and pioneering brands are shaping ...

Bitdefender, a global cybersecurity leader founded in Romania in 2001, announced the acquisition of a key division of ...

Zhida Hong, CEO of Addentax Group Corp. (NASDAQ:ATXG), recently acquired additional shares of the company, according to a filing with the Securities and Exchange Commission. The micro-cap company, ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Adani Group Chairman Gautam Adani has announced a major skill and employment initiative in partnership with Singapore’s ITEES. The initiative includes launching the world’s largest finishing school in ...

The pact will explore a range of applications across the BESS value chain, including utility-scale energy storage systems, ...

As of December 31, 2024, the Company had cash and cash equivalents in the amount of $15.6 million, compared to $5.3 million ...